Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“Localized pancreatic adenocancer treated with initial neoadjuvant FOLFIRINOX.
– ABC scoring.
– Anatomy (resectable, borderline resectable, or locally advanced), biology (baseline Ca19-9 >500), and condition (WHO performance status ≥1) were independent poor prognostic factors.
– Locally advanced=2 points, each of others=1 point,
– Survival graphic:
– A simple and practical way to gauge the prognosis of patients with localized pancreatic cancer in whom neoadjuvant FOLFIRINOX is planned.”
Source: Erman Akkus/X